We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Adaptimmune Therapeutics PLC | NASDAQ:ADAP | NASDAQ | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.10 | 1.05 | 1.32 | 0 | 09:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
Current Report
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of | (Commission File Number) | (IRS Employer Identification No.) |
(Address of principal executive offices, including zip code)
(
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol | Name of each exchange on which | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On November 1, 2023, Dr. Elliott Sigal, a member of the Board of Directors of Adaptimmune Therapeutics plc (the “Company” or “Adaptimmune”) resigned from the Company’s Board of Directors (the “Board”) effective on November 1, 2023. Dr. Sigal’s intention to resign from the Board when Dr. Kristen Hege’s appointment to the Board became effective on November 1, 2023 was previously announced by the Company on March 6, 2023 in connection with the strategic combination between Adaptimmune and TCR² Therapeutics Inc. Dr. Sigal’s decision to resign was not as a result of any disagreement with the Company or its management but was in order to more fully pursue other commitments.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
ADAPTIMMUNE THERAPEUTICS PLC | |||
Date: November 3, 2023 | By: | /s/ Margaret Henry | |
Name: | Margaret Henry | ||
Title: | Corporate Secretary |
Document and Entity Information |
Nov. 01, 2023 |
---|---|
Document and Entity Information [Abstract] | |
Document Type | 8-K |
Document Period End Date | Nov. 01, 2023 |
Securities Act File Number | 1-37368 |
Entity Registrant Name | ADAPTIMMUNE THERAPEUTICS PLC |
Entity Incorporation, State or Country Code | X0 |
Entity Tax Identification Number | 00-0000000 |
Entity Address, Address Line One | 60 Jubilee Avenue |
Entity Address, Address Line Two | Milton Park |
Entity Address, City or Town | Abingdon, Oxfordshire |
Entity Address, Postal Zip Code | OX14 4RX |
Entity Address, Country | GB |
City Area Code | 44 |
Local Phone Number | 1235 430000 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | American Depositary Shares, each representing 6 Ordinary Shares, par value £0.001 per share |
Trading Symbol | ADAP |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
Entity Central Index Key | 0001621227 |
Amendment Flag | false |
N-2 |
Nov. 01, 2023 |
---|---|
Cover [Abstract] | |
Entity Central Index Key | 0001621227 |
Amendment Flag | false |
Securities Act File Number | 1-37368 |
Document Type | 8-K |
Entity Registrant Name | ADAPTIMMUNE THERAPEUTICS PLC |
Entity Address, Address Line One | 60 Jubilee Avenue |
Entity Address, Address Line Two | Milton Park |
Entity Address, City or Town | Abingdon, Oxfordshire |
Entity Address, Postal Zip Code | OX14 4RX |
City Area Code | 44 |
Local Phone Number | 1235 430000 |
Entity Emerging Growth Company | false |
1 Year Adaptimmune Therapeutics Chart |
1 Month Adaptimmune Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions